Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).
BACKGROUND
Monoamine oxidase (MAO) inhibitors, despite the initial pharmacological interest, are used in clinic for their antidepressant effect and in the management of Parkinson symptoms, due to the established neuroprotective action. Efficacy and tolerability emerged from large-scale and randomized clinical trials.


METHODS
Thirty-six patents range from April 2012 to September 2014. The number of chemotypes with inhibitory effects on MAO is truly high (40 synthetic compounds, 22 natural products and 6 plant extracts reported and licensed), and the present review is comprehensive of all compounds, which have been patented for their relevance to clinical medicine in this period range (27 patents). Moreover, some of the collected patents deal with new formulations of compounds endowed with MAO inhibitory properties (two patents) and new therapeutic options/drug associations for already known MAO inhibitors (seven patents).


CONCLUSIONS
The patents reported in this review showed that the interest in this field is constant and mainly devoted to the study of selective MAO-B inhibitors, used as drugs for the treatment of neurological disorders. The development of novel human MAO inhibitors took advantage of the discovery of new therapeutic targets (cancer, hair loss, muscle dystrophies, cocaine addiction and inflammation), the recognized role of MAOs as molecular biomarkers and their activity in other tissues.
Sapienza University of Rome, Department of Drug Chemistry and Technologies , P.le A. Moro 5, 00185, Rome , Italy +39 06 49913149 ; +39 06 49913923 ; simone.carradori@uniroma1.it.
Simone
S
Carradori
Jacobus P
JP
Petzer
D000818:Animals; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D015394:Molecular Structure; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D009422:Nervous System Diseases / Q000188:drug therapy / Q000201:enzymology; D010330:Patents as Topic; D013329:Structure-Activity Relationship
D008996:Monoamine Oxidase Inhibitors
Alzheimer’s disease; Parkinson’s disease; depression; dual inhibitors; iron chelation; monoamine oxidase inhibitors; natural products